Institute of Allergy and Clinical Immunology, Seoul National University Medical Research Centre, Seoul, Korea.
Department of Translational Medicine, Seoul National University College of Medicine, Seoul, Korea.
Clin Exp Allergy. 2022 Apr;52(4):518-529. doi: 10.1111/cea.14077. Epub 2021 Dec 16.
Although lung macrophages are directly exposed to external stimuli, their exact immunologic roles in asthma are still largely unknown. The aim of this study was to investigate the anti-asthmatic effect of Acinetobacter lwoffii in terms of lung macrophage modulation.
Six-week-old female BALB/c mice were sensitized and challenged with ovalbumin (OVA) with or without intranasal administration of A. lwoffii during the sensitization period. Airway hyperresponsiveness and inflammation were evaluated. Using flow cytometry, macrophages were subclassified according to their activation status. In the in vitro study, a murine alveolar macrophage cell line (MH-S) treated with or without A. lwoffii before IL-13 stimulation were analysed by quantitative RT-PCR.
In a murine asthma model, the number of inflammatory cells, including macrophages and eosinophils, decreased in mice treated with A. lwoffii (A. lwoffii/OVA group) compared with untreated mice (OVA group). The enhanced expression of MHCII in macrophages in the OVA group was decreased by A. lwoffii treatment. M2 macrophage subtypes were significantly altered. A. lwoffii treatment decreased CD11b M2a and CD11b M2c macrophages, which showed strong positive correlations with Th2 cells, ILC2 and eosinophils. In contrast, CD11b M2b macrophages were significantly increased by A. lwoffii treatment and showed strong positive correlations with ILC1 and ILC3. In vitro, A. lwoffii down-regulated the expression of M2 markers related but up-regulated those related to M2b macrophages.
Intranasal A. lwoffii exposure suppresses asthma development by suppressing the type 2 response via modulating lung macrophage activation, shifting M2a and M2c macrophages to M2b macrophages.
尽管肺巨噬细胞直接暴露于外部刺激,但它们在哮喘中的确切免疫作用在很大程度上仍不清楚。本研究旨在探讨不动杆菌在调节肺巨噬细胞方面对哮喘的防治作用。
将 6 周龄雌性 BALB/c 小鼠用卵清蛋白(OVA)致敏和激发,在致敏期间通过鼻腔内给予不动杆菌。评估气道高反应性和炎症。使用流式细胞术根据其激活状态对巨噬细胞进行亚分类。在体外研究中,分析经或未经不动杆菌预处理的鼠肺泡巨噬细胞系(MH-S)在白细胞介素 13(IL-13)刺激前后的定量 RT-PCR。
在哮喘小鼠模型中,与未治疗的小鼠(OVA 组)相比,用不动杆菌(不动杆菌/OVA 组)治疗的小鼠的炎症细胞数量(包括巨噬细胞和嗜酸性粒细胞)减少。OVA 组中巨噬细胞 MHCII 的增强表达被不动杆菌治疗所降低。M2 巨噬细胞亚型发生显著改变。不动杆菌治疗减少了与 Th2 细胞、ILC2 和嗜酸性粒细胞呈强正相关的 CD11b M2a 和 CD11b M2c 巨噬细胞。相反,CD11b M2b 巨噬细胞被不动杆菌治疗显著增加,并与 ILC1 和 ILC3 呈强正相关。在体外,不动杆菌下调与 M2 相关的标志物的表达,但上调与 M2b 巨噬细胞相关的标志物的表达。
经鼻腔接触不动杆菌可通过调节肺巨噬细胞的激活来抑制 2 型反应,从而抑制哮喘的发展,将 M2a 和 M2c 巨噬细胞转化为 M2b 巨噬细胞。